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the thymus and lymph nodes only in mice that developed
GvHD.
Summary: This "ﬁrst-in-man" study demonstrated the
safety and feasibility of manufacturing both CD34-TK75+ T
cells and [18F]FHBG onsite for administration to patients. A
future upfront haploidentical transplant study will employ
100-fold more CD34-TK75 modiﬁed T cells.Table I
T-Rapa12 DLI T-Rapa6 DLI
Patient Characteristics
Number of Patients 40 44
Age (median, range) 51 (23-69) 48 (26-70)
# Prior Regimens (median, range) 3 (1-5) 3 (1-8)
Non-Hodgkins 19 (47.5%) 23 (52.3%)
Hodgkins/Gray Zone 6 (15.0%) 11 (25.0%)
Other Heme Malignancy 15 (37.5%) 10 (22.7%)
Diagnostic Risk Group, Kahl I 9 (22.5%) 7 (15.9%)
Kahl II 7 (17.5%) 8 (18.2%)
Kahl III 24 (60.0%) 29 (65.9%)
Chemotherapy Refractory 20 (50%) 21 (47.7%)
Kahl III and/or Refractory 29 (72.5%) 36 (81.8%)
Complete Remission (at HCT) 8 (20%) 12 (27.3%)
Chimerism (% donor; median
values)
Day 14 Post-HCT 60%T 35%
Myeloid
44% T 35%
Myeloid
Day 28 Post-HCT 87% T 79%
Myeloid
78%T 85%
Myeloid
Day 100 Past- HCT 94% T 99%
Myeloid
97% T 100%
Myeloid
GVHD
Classical Acute (through day 100) 4/40 (10%) 17/42 (40.5%)176
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In vitro CD34 enrichment of stem cell grafts is widely used for
depleting T cells from the graft. A high ex vivoT cell depletion
enables effective prevention of Graft-Versus Host Disease
(GVHD) e a major complication after allogeneic stem cell
transplantation. Until now, the clinical scale enrichment of
CD34 positive cells is a complex procedure involving
numerous manual steps.
We have developed a fully automated clinical scale process
within a closed sterile system to purify CD34+cells from
human leukapheresis products. In this context, cell washing,
erythrocyte reduction, cell labeling and the conditions for
immunomagnetic separation were optimized.
To determine the process performance, CD34+cells were
separated fromhuman leukapheresis products with an initial
volume of 120 mL to 211 mL (n¼5). We performed colony-
forming unit (CFU) assays, which allowed us to evaluate the
differentiation potential of the enriched cells.
The total processing time was <4 h. The number of enriched
CD34+ cells was 5.4x106 (range: 2.6x106 to 9.8x106). The
average yield was 73% and the average viability of the sepa-
rated CD34+ cells achieved 76% (range: 65.0% to 85.0%). The
depletion of CD34 negative cells was >99.9%. CFU assays per-
formed after the fully automated enrichment process showed
that the CD34+cell fraction contained primitive and multi-
potent progenitor cells, such as CFU-GEMM and CFU-GM.
The cell separation system described provides a safe and easy
way to purify CD34+ cells from leukapheresis within <4 h
without any intermediatemanual steps. The cell preparation in
a closed sterile system facilitates a fast and robust enrichment
ofCD34+cells.Thecells areeluted inavolumeofapproximately
80 mL and can be used directly for further applications.Acute GVHD Grade II (n¼3); III (n¼1) II (n¼14); III
(n¼3)
Acute GVHD Through Day 180,
Total
15/39 (38.5%) 28/42 (66.7%)
Gut involvement 7/39 (17.9%) 30/42 (47.6%)
Median Day of Onset Day 92 Day 70
Classical Chronic 17/37 (45.9%) 17/36 (47.2%)
(60 month
median F/U)
(38 month
median F/U)
Overall Outcome
K-M Survival Probability, Day 100
Post-HCT
95% 93.2%
One-year Post-HCT 75% 79.6%
Two-year Post-HCT 67.5% 63.6%
Current Survival, Overall 21/40 (52.5%) 28/44 (63.6%)
In Sustained CR 18/40 (45%) 21/44 (47.7%)
Death Due to PD (% of all patients) 17/40 (42.5%) 11/44 (25%)
In PR/CR (TRM) 2/40 (5.0%) 3/44 (6.8%)177
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In a phase II clinical trial, pre-emptive DLI using rapamycin-
resistant donor CD4+ T cells manufactured in 12-days
(T-Rapa12 cells) was associated with conversion of mixed
chimerism, GVL effects in patients with refractory hemato-
logic malignancy, and a moderate rate and severity of GVHD
(Blood, 2013). We recently found that culture interval trun-
cation to 6-days yielded T-Rapa6 cells with a unique gene
expression proﬁle (w6% of genes differentially expressed
relative to T-Rapa12 cells; Cytotherapy, 2013). To assess
whether T-Rapa6 cells mediate distinct clinical effects rela-
tive to T-Rapa12 cells, we conducted a sequential phase II
clinical trial (NCT0074490) at the NIH and Hackensack Uni-
versity Medical Center using the exact same low-intensity
transplant platform. T-Rapa6 cells were manufactured by ex
Abstracts / Biol Blood Marrow Transplant 20 (2014) S128eS150 S131vivo culture of donor CD4+ T cells using CD3/CD28 co-s-
timulation and IL-4, IL-2, and rapamycin. Differential in gene
expression proﬁle was conﬁrmed during trial implementa-
tion (n¼39 T-Rapa12 and T-Rapa6 products evaluated). As in
the initial trial, T-Rapa6 cells were infused at d14 post-HCT
(2.5 x 107 cells/kg). Patients (pts; n¼44) received outpatient
chemotherapy (until CD4 < 200 cells/ml) and then received
an HLA-matched sibling mobilized allograft. GVHD prophy-
laxis was cyclosporine plus short-course sirolimus (to d14
post-HCT); low-intensity conditioning was ﬂudarabine (120
mg/m2) and cyclophosphamide (1200 mg/m2). Relative to T-
Rapa12 pts, T-Rapa6 pts had similar characteristics (Table I):
36/44 (81.8%) of T-Rapa6 pts had a diagnosis at highest risk
for disease progression (Kahl III) and/or were chemotherapy
refractory (stable or progressive disease to last regimen).
Similar to T-Rapa12 pts, mixed chimerism existed prior to T-
Rapa6 DLI (median T and myeloid chimerism at d14 post-
HCT: 44% and 35%, respectively). Similar to T-Rapa12 pts,
T-Rapa6 pts had a rapid increase in donor chimerism by d28
post-HCT with continued advancement towards full donor
chimerism by d100 post-HCT. Relative to T-Rapa12 pts, T-
Rapa6 pts had an increased frequency of acute GVHD at days
100 and 180 post-HCT; this increase was primarily attribut-
able to steroid-responsive gut disease. Chronic GVHD inci-
dence did not appear to be substantially increased in T-Rapa6
pts. T-Rapa6 and T-Rapa12 pts had similar survival probabil-
ities and frequency of sustained complete remission; in each
cohort, deaths were primarily due to progressive disease.
These data provide further support for evaluation of T-Rapa
cell pre-emptive DLI after low-intensity allogeneic HCT as
this approach associates with consistent alloengraftment,
sustained complete remissions, and low transplant-related
mortality. The differential gene expression proﬁle existent
between T-Rapa12 and T-Rapa6 cells is sufﬁcient to drive
differential acute GVHD effects.178
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Adoptive transfer of CMVpp65-speciﬁc T-cells(cCTL) from
CMV-seropositive(CMVpos) donors effectively restores anti-
viral-immunity after stem cell transplantation. However, the
naïve T-cells in cord blood(CB) and adult CMV-seronegati-
ve(CMVneg) donors require different culture systems togenerate cCTL. With a novel GMP-applicable protocol we
have reliably generated cCTL from CB and found that 15/15
CB T-cell lines recognized atypical epitopes of pp65. We then
expanded cCTL from CMVneg donors in a GMP-applicable
way by isolating naive T-cells and stimulating them with
pp65-Pepmix-pulsed antigen-presenting cells supple-
mented with IL2,IL7,IL12, and IL15. cCTL expanded from 8/11
CMVneg donors were primarily CD8+ T-cells(mean 71%).
cCTL secreted IFN-g in response to pp65-peptides(mean 224
spots) as measured in Elispot assays and lysed pp65-pulsed
target cells. cCTL derived from naive T-cells recognized only
novel and atypical pp65 epitopes (e.g. LQTGIHVR,MLNIP-
SINV) but not the typical epitope NLVPMVATV as conﬁrmed
by ELISPOT and Pentamer. Analysis of the avidity of naïve
donor CTL speciﬁc for the atypical CMV epitopes revealed
that the 1/2 -maximum effective concentration was similar
(mean:600pM) to CMVpos CTL recognizing typical epito-
pes(mean: 300pM), and more avid than CMVpos CTL
recognizing atypical epitopes(mean:4nM). TCR sequencing
performed on T-cells speciﬁc for typical(CMVpos) and aty-
pical(CMVpos,CMVneg, and CB) epitopes revealed that
CMVpos donor cCTL recognizing typical epitopes were
markedly less polyclonal. To address the concern that atyp-
ical epitopes might not be naturally presented by CMV-
infected cells and therefore not recognized by in vitro
generated CTL, we tested whether cCTL generated using CMV
AD169-infected ﬁbroblasts would recognize the same epi-
topes. CMVpos cCTL recognized typical epitopes while CB/
CMVneg cCTL recognized only atypical epitopes, suggesting
that the epitopes are naturally processed/presented by APCs.
Using deep TCR sequencing from the peripheral blood of CBT
recipients, the atypical epitope MLN was found in a similar
number of HLA-A2+ patients (6/9) than the typical epitope
(NLV) (5/9). These results reveal major, previously-unre-
ported differences in the naïve and memory CMV speciﬁc T-
cell repertoire but suggest that atypical epitopes may indeed
be important. Hence, we demonstrated that atypical epi-
topes are naturally presented by CMV-infected cells and are
now evaluating the clinical efﬁcacy of these CTL in recipients
of CBT.179
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Adoptive transfer of virus-speciﬁc T-cells (CTLs) from HLA
partially matched 3rdparty donors can effectively treat EBV,
CMV or Adv infections in recipients of HSCT from seroneg-
ative or cord blood donors. However, in vitro generated CTLs
selectively react against 1-3 immunodominant (ID) epitopes
(eps) presented by 1-2 HLA alleles. Therefore, to be effective,
it is critical that administered CTLs respond to eps presented
by HLA alleles shared by the recipient. To address this, we
established a bank of 123 GMP grade CMV-CTLs generated
using CMVpp65 peptide pool loaded autologous APCs. Each
